Skip to main content

Guidelines Updated for Nonoccupational Postexposure Prophylaxis for HIV

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on May 9, 2025.

via HealthDay

FRIDAY, May 9, 2025 -- Updated recommendations for antiretroviral nonoccupational postexposure prophylaxis (nPEP) for HIV have been published in the May 8 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Mary R. Tanner, M.D., from the CDC in Atlanta, and colleagues updated the 2016 nPEP guidelines and considerations for use in the United States, including considerations for testing and nPEP regimens for persons exposed who have received long-acting injectable antiretroviral agents in the past.

The authors note that for most adults and adolescents, the preferred regimens are bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir plus (tenofovir alafenamide or tenofovir disoproxil fumarate) plus (emtricitabine or lamivudine). The regimens can be tailored to specific clinical circumstances. For persons prescribed nPEP, medical follow-up should also be tailored to the clinical situation; recommended follow-up includes a remote or in-person visit with a medical provider at 24 hours and clinical follow-up at four to six and 12 weeks after exposure for laboratory testing. Persons initiating nPEP should be informed that preexposure prophylaxis (PrEP) can reduce their risk for acquiring HIV in the case of repeat or continuing exposure after the nPEP course. PrEP options should be offered to those with ongoing indications, and an nPEP-to-PrEP transition plan should be created.

"Communication and education strategies are needed to increase both provider and community awareness of nPEP," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Helping Others Linked to Higher Level of Cognitive Function

THURSDAY, Aug. 21, 2025 -- Helping others, both via formal volunteering and informal helping, is associated with higher levels of cognitive function and slower cognitive decline...

TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer

THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical...

Work-Related Income Drops for Parents of Children Diagnosed With Type 1 Diabetes

THURSDAY, Aug. 21, 2025 -- Work-related income decreases sharply for mothers and fathers of children diagnosed with type 1 diabetes, with similar effects across sociodemographic...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.